Gallium-68 DOTATATE - Advanced Accelerator Applications
Alternative Names: 68Ga-DOTA-TATE; 68Ga-DOTA-tyr3-Octreotate; DOTATATE-Ga68; GA-68 DOTATATE; GalioMedix; NETSPOT; SomaKit TOC; Somakit-TATELatest Information Update: 05 Apr 2024
At a glance
- Originator Advanced Accelerator Applications
- Developer Advanced Accelerator Applications; Assistance Publique - Hopitaux de Marseille; Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Radio-Isotope Therapy of America Foundation; RadioMedix
- Class Imaging agents; Organometallic compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuroendocrine tumours
Most Recent Events
- 21 Mar 2024 Phase-III clinical trials in Neuroendocrine tumours (Diagnosis) in Japan (IV) (NCT06240741)
- 05 Feb 2024 Novartis plans a phase III trial for Neuroendocrine tumors in Japan (IV) in March 2023 (NCT06240741)
- 11 Nov 2021 Novartis plans a phase I trial in Glioblastoma (Combination therapy, Monotherapy, Recurrent, First line therapy) (NCT05109728), in February 2022